Camber Capital Management LP Glaukos Corp Transaction History

Camber Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$45.44 - $71.21 $8.63 Million - $13.5 Million	-190,000 Reduced 54.29%	160,000 $11.4 Million
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $7.63 Million - $9.53 Million	162,978 Added 87.14%	350,000 $18.6 Million
Q1 2022 May 16, 2022	BUY	$44.33 - $57.82 $4.97 Million - $6.48 Million	112,022 Added 149.36%	187,022 $10.8 Million
Q4 2021 Feb 14, 2022	BUY	$40.27 - $56.99 $3.02 Million - $4.27 Million	75,000 New	75,000 $3.33 Million
Q3 2020 Nov 16, 2020	SELL	$37.23 - $50.97 $27.2 Million - $37.2 Million	-730,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$28.78 - $46.83 $21 Million - $34.2 Million	730,000 New	730,000 $28 Million

352

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.48B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.